All In Biotech

Drug Trial Radar · NCT05300048

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

34

Actual

Start

Apr 22, 2022

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Faeth TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.

Conditions

  • Advanced Solid Tumor
  • PIK3CA Mutation
  • PTEN Loss of Function Mutation

Interventions

  • SerabelisibDrug

    serabelisib administered orally

  • Insulin Suppressing DietOther

    3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

  • Nab paclitaxelDrug

    nab-paclitaxel administered intravenously weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts 1a/1b: Evaluate safetyTime frame: Through study completion, up to 12 months.
  2. Cohorts 1a/1b: Evaluate complianceTime frame: Through study completion, up to 12 months.
  3. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Cmax.Time frame: Through study completion, up to 12 months.
  4. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring Tmax.Time frame: Through study completion, up to 12 months.
  5. Cohorts 1a/1b: Evaluate the pharmacokinetic impact by measuring AUC.Time frame: Through study completion, up to 12 months.
  6. Cohorts 2, 3, 4: Use the Objective Response Rate (ORR) to assess the antitumor efficacy of serabelisib in combination with a Study ISD.Time frame: Through study completion, an average of 8 months.

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Pacific Cancer Specialists

    Anaheim, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Community Health Network, Inc.

    Indianapolis, Indiana

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • New Jersey Cancer Care, PA

    Belleville, New Jersey

  • Englewood Health

    Englewood, New Jersey

  • Northwell Health

    Lake Success, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • East Carolina University

    Greenville, North Carolina

  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Baptist Hospitals of Southeast Texas

    Beaumont, Texas

  • Oncology Consultants, PA

    Houston, Texas

  • Lumi Research

    Kingwood, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.